A Libtayo combo fails to beat Keytruda in first-line melanoma.

The company discontinues the Lag3 project in lung cancer.

The company gets another odronextamab knockback, while a key fianlimab readout is postponed.

Opdualag chalks up another failure, this time in the extension of an approved use.

Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.

Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.

The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.

Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.

After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.